Lupin Secures CDSCO Panel Nod for Phase IV Trial of Budesonide-Based COPD Inhaler
Advertisement
New Delhi: Lupin Limited has received recommendations from the Subject Expert Committee, under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase IV clinical trial of its fixed-dose combination (FDC) inhaler containing Budesonide IP 200 mcg + Glycopyrronium Bromide eq. to Glycopyrronium 12.5 mcg + Formoterol Fumarate Dihydrate IP 6 mcg (Metered Dose Inhaler).
The proposal was presented in light of the condition mentioned in permission in Form CT-23 dated 25.04.2025.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.